Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156388 | 0.89 | ALOX5 (0.39) | ALOX5NR4A1NR4A2NR4A3BCL2 | |
| SCHEMBL6155637 | 0.86 | MAOB (0.40) | APPNR4A1NR4A2NR4A3BCL2 | |
| SCHEMBL6156481 | 0.85 | MAOB (0.39) | APPALOX5NR4A1NR4A2NR4A3 | |
| SCHEMBL6154726 | 0.84 | APP (0.39) | APPALOX5NR4A1NR4A2NR4A3 | |
| SCHEMBL4169944 | 0.82 | VDR (0.50) | APPALOX5NR4A1NR4A2NR4A3 | |
| SCHEMBL2785504 | 0.81 | CYSLTR2 (0.40) | ALOX5 | |
| SCHEMBL6158294 | 0.80 | PDK1 (0.41) | APPMAOBPKM | |
| SCHEMBL6155616 | 0.80 | ALOX5 (0.39) | ALOX5 | |
| SCHEMBL6883442 | 0.79 | BCHE (0.52) | — | |
| SCHEMBL6155510 | 0.79 | MAPK1 (0.39) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-01 | — | — | US | claimed |
| EP-1686972-B1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RES & DEV (FR) | 2008-03-12 | — | — | EP | claimed |
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2007-02-22 | — | — | US | claimed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | claimed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | claimed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | claimed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | claimed |
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-01 | — | — | US | disclosed |
| EP-1952808-A2 | Composition in the form of a spray comprising calcitriol | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-08-06 | — | — | EP | disclosed |
| EP-1686972-B1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RES & DEV (FR) | 2008-03-12 | — | — | EP | disclosed |
| US-20070135379-A1 | Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-06-14 | — | — | US | disclosed |
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2007-02-22 | — | — | US | disclosed |
| EP-1686972-A1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | Galderma Research & Development, S.N.C. (FR) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005053666-A1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | WO | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135379-A1 | Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle | IDUA, ARSA, STS | APP 1068/4885ALOX5 3356/4885NR4A1 3260/4885 |
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | CYP24A1, CYP2R1, VDR | APP 67/4885ALOX5 153/4885NR4A1 638/4885 |
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | CYP19A1, CYP17A1, CYP51A1 | APP 2057/4885ALOX5 85/4885NR4A1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.